Publications

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

http://onlinelibrary.wiley.com/doi/10.1002/mgg3.334/full

purple brain
Image Source

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

https://www.ncbi.nlm.nih.gov/pubmed/28478033

egcg-leaf
Image Source

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model

https://www.ncbi.nlm.nih.gov/pubmed/26363314

brain-green-tea1
Image Source